Clinical Trials

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer




Protocol Principal Investigator

Hamid Emamekhoo, MD


University of Wisconsin Carbone Cancer Center


The purpose of this study is to evaluate the safety of an investigational DNA vaccine, pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with nivolumab, and the efficacy of this combination in decreasing serum Prostate-Specific Antigen (PSA) in patients with non-metastatic, non-castrate prostate cancer (clinical stage D0/M0).

Start Date

December 10, 2018

Estimated Primary Completion Date

October 31, 2020

Estimated  Completion Date

October 31, 2022


University of Wisconsin-Madison
Bristol-Meyers Squibb
Madison Vaccines, Inc (MVI)
AIQ Solutions

Interested in participating? Contact the UW Carbone Cancer Center